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Background: To determine the incidence rate and to describe other basic epidemiological data of primary brain
tumours in a population-based study in Georgia, performed between March 2009 and March 2011.
Methods: Active case ascertainment was used to identify brain tumour cases by searching neuroradiology scan
reports and medical records from all participating medical institutions, covering almost 100% of the neurooncology
patients in the country.
Results: A total of 980 new cases were identified during the two-year period. For a population of almost 4.5 million,
the overall annual incidence rate was 10.62 per 100,000 person-years, age-standardized to the year 2000 US population
(ASR). Non-malignant tumours constituted about 65.5% of all tumours. Males accounted for 44% and females for 56%
of the cases. Among classified tumours, age-standardized incidence rates by histology were highest for meningiomas
(2.65/100,000), pituitary adenoma (1.23/100,000) and glioblastomas (0.51/100,000). ASR were higher among females than
males for all primary brain tumours (10.35 vs. 9.48/100,000) as well as for main histology groups except for
neuroepithelial, lymphomas and germ cell tumours.
Conclusions: The annual incidence rate of all primary brain tumours in Georgia, though comparable with some
European registry data, is low in comparison with the 2004–2005 Central Brain Tumor Registry of the United States
(CBTRUS) database, which may reflect variations in reporting and methodology. The higher percentage of unclassified
tumours (37.8%) probably also affects the discrepancies between our and CBTRUS findings. However, the most
frequently reported tumour was meningioma with a significant predominance in females, which is consistent with
CBTRUS data.
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The determination of incident brain tumour cases is im-
portant in order to describe disease patterns and to iden-
tify the causes of the disease, and it is essential for the
management, evaluation and planning of healthcare ser-
vices for disease control.
Information about incidence rates of primary brain tu-
mours in Georgia during last decades was only available
from hospital-based pilot studies. According to these stud-
ies carried out in the Sarajishvili Institute of Neurology &
Neurosurgery in 1996–2000, meningioma and glioblast-
oma were the most frequent diagnosed tumours and* Correspondence: epigeo@hotmail.com
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distribution, and reproduction in any mediumaccounted for approximately 2/3 of all primary brain tu-
mours [1]. At that time, new imaging techniques, which
can enhance cancer detection rate, were established and
situated only at hospital departments. In past decade, the
situation changed radically. With some delay, advanced
neuroimaging machines have been widely introduced in
Georgia, and several state-of-art 1.5 tesla MRI units and
multi-slice CT scanners are available both in clinical and
ambulatory settings. Since imaging of the brain provides ac-
curate information about brain structures, nowadays, a pa-
tient with a suspected brain tumour is routinely examined
by an imaging diagnostic tool, which is a painless, noninva-
sive and fast medical test. In these circumstances, a review
of CT and MRI results is a necessary step for obtaining ac-
curate information about brain tumour incidence.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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population-based study performed in Georgia aiming to
examine the incidence and the clinical and pathological
features of primary malignant and non-malignant brain
tumours. The first year results of the study have been re-
ported recently [2]. We performed the analysis of two
years data in order to increase the statistical power. In the
absence of a national population-based brain cancer regis-
try and, therefore, standard tumor registration procedures
and training, cases are ascertained by an active search of
neurosurgery hospital records and scan reports from CT
and MRI units. This method allows for a precise estima-
tion of the proportion of patients that are diagnosed only
neuroradiologically and of those that undergo surgery with
further histological verification.Methods
The cancer cases included in this study were patients diag-
nosed with primary brain tumour in Georgia between
March 1st, 2009 and March 1st, 2011. All cases were coded
following the International Classification of Diseases for
Oncology, Third Edition (ICD-O-3). The information about
the patients was gained from participating medical institu-
tions: 15 different hospitals providing neurosurgical
and neuroradiological services and numerous separate
ambulatory-based CT and MRI units located in three
large cities (Tbilisi, Kutaisi and Batumi). According to
our estimates the participating medical facilities repre-
sent almost 100% of the neurooncological activity in the
country. Ethical approval was obtained from the Tbilisi
State University Medical Faculty ethics committee.
The active case ascertainment was used in order to cap-
ture all cases of newly diagnosed brain tumours within the
study period. Relevant information (including socioeco-
nomic, clinical, pathological, radiological and other details)
was regularly collected by our representatives from the
participating hospitals and neuroradiological units using a
specially designed cancer case reporting form. Along with
the written form, all collected data was kept in an elec-
tronic database. The cases were identified from: (1) medi-
cal records of all neurosurgical patients with a discharge
cancer diagnosis, and (2) scan reports containing any
suspicion of a brain tumour. Scan reports were further
reviewed by a neurosurgeon to identify incident cases of
primary brain tumours and to formulate a diagnosis for
each selected case. If the description was limited, the
tumor was qualified as ‘unclassified’. All final radiological
cases were matched with the surgical cases to find possible
duplicates and eliminate it in favour of the surgery report.
If the diagnoses of the same patient differed between the
radiological and the surgical database, the case was dis-
cussed with a neurosurgeon and the neurologist (DG) to
obtain a single final diagnosis.To ensure the completeness of the collected data, add-
itional sources of information were used. The surgery
database of the neurosurgical departments in Tbilisi hos-
pitals and the large pathology database in Tbilisi were
searched for cases coded with a brain cancer. For further
verification, data obtained from clinical and radiological
sources were checked against a histological database and
in case of any disagreement over the diagnosis the diag-
nosis from pathology report was kept.
Selection criteria included all cases of intracranially lo-
cated malignant or non-malignant tumours and excluded
cases of recurrent brain tumour and extracranial tumour
with invasion into cranium. Intracranial tumours that orig-
inated from the brain itself, meninges, cranial nerves, pitu-
itary and pineal glands and craniopharyngeal duct were
included in the study, according to the internationally rec-
ognized primary brain tumour standard definition [3]. The
latest WHO 2007 histological classification of tumours of
the central nervous system was used to classify cases into
six main histology groups: neuroepithelial tumours, tu-
mours of cranial and paracranial nerves, tumours of men-
inges, lymphomas and hematopoetic tumours, germ cell
tumours and sellar region tumours [4].
The following information was selected and stored in
the cancer case reporting form: demographics, diagnosis
details (grade, behaviour, diagnosis confirmation method
and date of diagnosis), treatment (surgery, radio- or
chemotherapy), vital status and possible risk factor expos-
ure. Behaviour code (0, 1, 3) was specified according to
the ICD-O-3. Non–malignant primary brain tumors in-
clude those tumors with a benign behavior code of “0” or
uncertain behavior code of “1”. The date of the first brain
scan when cancer was detected was defined as the date of
diagnosis. Besides tumour behaviour and grade three other
variables were used to characterize a cancer type: histology
group, specific histology and ICD-O-3 morphology code.
Using these variables, we tried to further classify all un-
formulated diagnoses as much as possible based on avail-
able data.
STATA and Microsoft Excel were used to calculate
crude incidence rates, incidence rate ratio, frequency,
arithmetic means of parameters and 95% confidence inter-
vals (CIs) within the cohort and subgroups. Groups were
compared by Student’s t test and the χ2 test for continuous
variables and proportions, respectively. The denominator
used for the analysis was the Georgian population in 2009
and in 2010, thus person-years at risk were calculated
by summarizing the population data of both years. Age-
standardization was performed based on five-year age
groups across the whole age spectrum (total of 18 groups)
and standardized to the US 2000 population in order to
directly compare our incidence rates to those of the US
Central Brain Tumor Registry (CBTRUS) since it contains
the largest compilation of population–based data on the
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group consisted of less than 20 patients ASR and corre-
sponding 95% CIs were not calculated. Calculating age-
standardized rates (direct standardisation), standard errors,
and 95% CIs of the standardized rate ratio (SRR) between
groups selected by sex and histology were performed ac-
cording to the method described by Boyle and Parkin [6].
Results
Basic characteristics
A total of 980 newly diagnosed cases of primary brain
tumours were identified in the two-year period between
March 2009 and March 2011. 44% of cases were male.
According to the National Statistics Office of Georgia in
2009 there were 4.385 million inhabitants and4.436 mil-
lion inhabitants in 2010 [7]. The mean age at diagnosis
was 48.9 years (standard deviation [SD] 18.1 years). In
the population below 20 years of age, only 83 cases were
identified (8.5%). In 59.5% of the cases, the diagnoses
were based on neuroradiological data; histological con-
firmation was received in 35.7%, and in the remaining
4.8% tumours were diagnosed based solely on clinical
data (i.e., either the medical record did not contain a
pathology report or pathology report was not available
at the moment of data collection). Less than half of the
patients (n = 404, 41.2%) underwent neurosurgical interven-
tion. Some data sources (mostly scan reports) had incom-
plete demographic and/or clinical information, therefore
several variables had missing values (as shown in Table 1);
the numbers and percentages presented in text and tables
are based on available data only.
Overall incidence of brain tumours
The crude incidence rate was 11.11 per 100,000 person-
years, whereas the overall annual age-standardized inci-
dence rate (ASR) per 100,000 person-years was 10.62
(Table 2), with similar rates in 2009 (10.25) and 2010
(10.99). Among specified neoplasms (n = 444), benign and
borderline tumours accounted for 65.5% (ASR = 3.15) and
malignant brain tumours for the remaining 34.5% (ASR =
1.67). The difference in ASRs between benign/borderlineTable 1 Percentage of missing values in several variables
Variables Total Missing (%) Unclassified (%)
Case numbers 980 0 -
Age 977 0.3% -
Sex 916 6.5% -
Histology group 980 0 37.8%
Specific histology 973 0.7% 37.8%
ICD-O morphology code 980 0 Unspecified 40.7%
Tumor behaviour 444 54.5% -
Tumor grade 377 61.5% -and malignant tumors was statistically significant (SRR =
1.88, 95% CI: 1.55; 2.29). The dominance of non-malignant
over malignant tumours was observed in both years.Distribution and incidence rates by histology
The most frequent tumours by reported histology after ex-
cluding unclassified tumours were non-malignant men-
ingiomas (n = 254, 43.7%), followed by tumours of sellar
region (n = 130, 22.4%) (Figure 1). Gliomas, the most ag-
gressive malignant brain tumours (astrocytic, oligodendro-
glial, oligoastrocytic and ependimal origin), represented
19.6% (n = 114) of all brain tumours. The distribution of
glial tumours by specific histology is represented in Figure 2.
Within this group, glioblastoma accounted for the majority
of glioma.
Age-standardized and crude incidence rates among
histology groups are shown in Table 2. The highest ASRs
were observed for tumours of meninges (2.97 per
100,000 person-years), sellar region (1.40) and neuroepi-
thelial tumours (1.43). Within specific histologies, ASRs
were as follows: meningiomas (2.65), pituitary adenomas
(1.23), glioblastomas (0.51) and neurinomas (0.34).Incidence rates and distribution by sex
The overall ASR was higher among females (10.35 ver-
sus 9.48 per 100,000 person-years) than males, but the
difference was not statistically significant. Standardized
incidence rates for non-malignant tumours were 1.5
times higher in females as compared to males (3.59 vs
2.36; SRR = 1.52, 95% CI: 1.19; 1.93), whereas for ma-
lignant tumours ASRs were 1.3 time higher in males
than in females (1.92 vs 1.46 respectively; SRR = 1.32,
95% CI: 0.95; 1.82). Crude incidence rates by age are
presented in Table 3.
For most of histology groups, primary brain tumours
were more frequent in females as compared to males.
The difference between ASRs was statistically significant
for tumors of the meninges (3.33 vs 2.20) and of the
sellar region (1.57 vs 0.93). In contrast, for specific tu-
mours incidence rates of glioblastomas, embryonal tu-
mours (medulloblastoma), lymphomas and germinomas
were higher in males than in females, but the differences
were not statistically significant (Table 2).Age distribution
Age-specific crude incidence rates for all tumours and
selected histology groups are illustrated in Figure 3.
Age-specific incidence rates were low for patients in late
childhood and adolescence with a prominently increas-
ing tendency in adulthood and a peak within the age
range of 65–74 years.
Table 2 Crude and age-standardized incidence rates of primary brain tumours by sex (per 100,000 person-years)
Group Specific histology WHO histology code N % IR
Females Males
ASR (CIs) N % IR ASR (CIs) N % IR ASR (CIs) SRR (CIs)
Neuroepithelial 129 13.16 1.46 1.43 (1.18-1.68) 62 12.1 1.33 1.26 (0.94-1.58) 65 16.1 1.55 1.56 (1.18-1.95) 0.81 (0.57-1.15)
Pilocytic astrocytoma 9421 6 0.61 0.07 2 0.4 0.04 4 1.0 0.09
Diffuse astrocytoma 9420, 9400 11 1.12 0.13 5 1.0 0.11 6 1.5 0.14
Anaplastic astrocytoma 9401 14 1.43 0.16 7 1.4 0.15 7 1.7 0.17
Glioblastoma 9440, 9441 48 4.89 0.54 0.51 (0.36-0.66) 22 4.3 0.47 0.42 (0.24-0.60) 26 6.4 0.62 0.62 (0.38-0.86) 0.68 (0.38-1.22)
Other astrocytomas 9450 7 0.71 0.08 1 0.2 1 0.25 0.02
Oligodendroglioma 9451 5 0.51 0.06 4 0.8 0.08 3 0.7 0.07
Anaplastic
oligodendroglioma
9391, 9392 4 0.41 0.04 2 0.4 0.04 3 0.7 0.07
Oligoastrocytoma 9424, 9425 2 0.2 0.02 9 1.7 0.19 8 2.0 0.19
Ependymoma 9382 17 1.73 0.19 3 0.6 0.06 1 0.25 0.02
Neuronal - glial 9470, 9471 7 0.71 0.08 5 1.0 1 0.25 0.02
Embryonal -
Medulloblastoma
9505, 9506, 9493 8 0.81 0.09 2 0.4 0.04 5 1.2 0.12
Tumours of cranial
and spinal nerves
Neurinoma 9560 31 3.17 0.35 0.34 (0.22-0.46) 20 3.9 0.43 0.4 (0.22-0.58) 10 2.5 0.24 0.25 (0.09-0.40) 1.61 (0.77-3.37)
Tumours of meninges 284 28.98 3.22 2.97 (2.62-3.32) 173 33.7 3.73 3.33 (2.82-3.84) 96 23.7 2.29 2.20 (1.76-2.65) 1.51 (1.18-1.93)
Meningioma 9530, 9531, 9532, 9533,
9534, 9537, 9539





21 2.14 0.24 11 2.1 0.24 9 2.2 0.21
Haemangioblastoma 9161 9 0.92 0.10 4 0.8 0.08 4 1 0.09
Lymphomas Lymphoma 9590 3 0.3 0.03 1 0.2 0.02 2 0.5 0.04
Germ cell Germinoma 9064, 9080 4 0.41 0.04 1 0.2 0.02 3 0.7 0.07
Tumours of the
sellar region
130 13.26 1.47 1.40 (1.16-1.65) 76 14.8 1.64 1.57 (1.21-1.93) 41 10.1 0.98 0.93 (0.65-1.22) 1.69 (1.16-2.45)
Pituitary adenoma 8272 115 11.73 1.30 1.23 (1.00-1.46 67 13.1 1.44 1.36 (1.04-1.69) 36 8.9 0.86 0.82 (0.55-1.09) 1.67 (1.12-2.48)
Craniopharyngioma 9350 15 1.53 0.17 9 1.7 0.19 5 1.2 0.12
Unclassified Unclassified 8000 399 40.71 179 34.9 187 46.3
Total 980 11.11 10.62 (9.94-11.29) 512 11.05 10.35 (9.44-11.26) 404 9.64 9.47 (8.54- 10.41) 1.09 (0.96-1.25)


































































Figure 1 Distribution of primary brain tumours by histology (excluding unclassified cases).
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Comparison of incidence rates between registries
The present population-based study performed in the
Caucasus region aimed to assess the incidence and clinical
and pathological features of primary brain tumours using
the WHO 2007 histological classification of tumours of
the central nervous system. The observed overall ASR of
primary brain tumours (10.62 per 100,000 person-years) is
lower than the standardized rate of primary brain and
CNS tumours diagnosed in 2004–2005 in the US and re-
ported in 2009 by CBTRUS (18.16) and also lower than
ASR reported by the Austrian Brain Tumour Registry
(ABTR) in 2005 (18.1) [8,9]. Lower incidence rates com-
pared with the CBTRUS database were also observed in
our study for the main histology groups and specific his-















Figure 2 Distribution of all primary brain gliomas by specific histologdata, recent publications from some European registries
reported incidence rates of primary brain tumours similar
to ours (8.5-14 per 100,000 person-years) [10-13].
The difference in the incidence rates may be due to sev-
eral reasons. For example, a lower incidence rate in Georgia
than in more affluent countries may reflect the low atten-
tion to subtle and sometimes obscure symptoms of brain
tumours and as a consequence low healthcare utilization,
complicated by insufficient or lack of health insurance
coverage among the population. Additionally, CT and MRI
imaging systems are concentrated only in large cities and
therefore these diagnostic methods are too expensive and
inaccessible for large parts of the rural population. A fur-
ther, statistical explanation is that a high percentage of
Georgian emigrants, who are looking for a job abroad





ies (n = 114).
Table 3 Crude incidence rates of brain tumours by age and sex in 2009–2010 (per 100,000 person-years)
Total Female Male













0 - 4 15 504,300 2.97 6 235,500 2.55 7 268,800 2.60
5 - 9 24 458,100 5.24 7 216,600 3.23 15 241,500 6.21
10 - 14 12 543,700 2.21 6 259,900 2.31 6 283,800 2.11
15 - 19 32 696,600 4.59 9 342,000 2.63 17 354,600 4.79
20 - 24 27 724,400 3.73 11 358,000 3.07 13 366,400 3.55
25 - 29 34 676,000 5.03 17 336,800 5.05 12 339,200 3.54
30 - 34 64 629,900 10.16 35 320,100 10.93 25 309,800 8.07
35 - 39 55 606,200 9.07 31 312,700 9.91 24 293,500 8.18
40 - 44 87 592,800 14.68 47 312,900 15.02 37 279,900 13.22
45 - 49 90 672,100 13.39 47 360,400 13.04 38 311,700 12.19
50 - 54 139 593,100 23.44 81 319,900 25.32 54 273,200 19.76
55 - 59 94 510,700 18.41 54 279,400 19.33 38 231,300 16.43
60 - 64 101 361,700 27.92 49 200,400 24.45 44 161,300 27.28
65 - 69 71 333,600 21.28 40 197,300 20.27 26 136,300 19.07
70 - 74 90 392,100 22.95 47 234,900 20.01 34 157,200 21.63
75 - 79 33 258,600 12.76 15 158,900 9.44 12 99,700 12.04
80 - 84 8 180,300 4.44 7 118,200 5.92 1 62,100 1.61
85+ 1 87,600 1.14 1 68,200 1.47 0 19,400 0
Unspecified 3 2 1
Total 980 8,821,800 11.11 512 4,632,100 11.05 404 4,189,700 9.64
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the World Bank), can artificially increase the denominator
(i.e., ‘true’ population number is less than the official one)
[14]. Finally, differences between countries in sociodemo-
graphic characteristics and environmental factors (so-called























Figure 3 Age-specific crude incidence rates of primary brain tumoursbrain tumour risk, should be taken into account when
interpreting ASRs of different countries.
Direct comparison to CBTRUS statistical report
The comparison of tumour distribution patterns by be-
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particular the predominance of non-malignant over ma-
lignant tumours, with the most common histology being
meningioma, and glioblastoma representing the most
frequent type of gliomas. However, some slight differ-
ences can be found in distribution of specific tumour
types according to their frequency as shown in Figure 1.
For the majority of tumours, incidence rates were higher
among females than males, but for specific tumours the
strongest differences by sex were observed for meningi-
omas and pituitary adenomas (common in females) and
for glioblastoma and germ cell tumours (common in
males). These results are concordant with those in the
CBTRUS and ABTR reports, which may indicate the val-
idity of our data. Moreover, age-specific rate curves for
brain tumours among the registries were nearly identical
with a prominent increase of the incidence rate after ap-
proximately 30 years of age and a decline in those over
75 years old. The drop in incidence is evident in our and
ABTR data, but less pronounced in the CBTRUS report.
Study limitations and next steps for improving validity of
the data
Our study has limitations caused by the relatively low
rate of histologically confirmed tumours (36%). In con-
trast, histological verification rate is 69% in CBTRUS re-
port and 80.9% in the ABTR data. In other studies,
however, pathological confirmation index varied widely
from 35% to 59% [11,15,16]. The percentage of histologi-
cally verified cases is one of the registry reliability indica-
tors and efforts should be directed towards improving this
value, which is less likely to reflect bias in reporting cancer
cases (the index in our study is persistently low in both
years – 38% and 33.5%, respectively). There is some evi-
dence in the literature, however, that because non-invasive
neuroimaging techniques improve and become an import-
ant diagnostic tool today, the proportion of radiologically
diagnosed tumor cases has increased, especially among
older patients. Indeed, 41% of the histologically unverified
tumours in the population-based cancer registry of Spanish
province Girona were explained by easy access to sophisti-
cated imaging tools [15]. We suggest that a limited
neurosurgical activity in elderly patients, among whom
nonsurgical treatment options are usually unavailable
(in particular for patients in rural areas), contributes to
higher number of neuroradiologically confirmed diag-
noses. This is mostly also due to delays in diagnosis
leading to presentation with advanced disease. All these
factors predicted the relatively high proportion of un-
classified tumours in our study. Indeed, our data con-
firm that radiologically defined cases constitute about
90% (n = 362) of unclassified group. The peak of purely
radiologically identified cases with no further classifica-
tion was observed in the age group 50–54 years and thepercentage is persistently high up to 75 years of age. Ana-
lysing the causes of absence of histological verification
among cases with suspected brain tumour is out of the
scope of this study, but the following factors can be dis-
cussed. In addition to the above mentioned observation,
cultural, educational and economical factors may predis-
pose to a low level of activity among suspected patients,
who are not motivated to visit a specialized neurooncology
center. Also, an existing cancer program and the activity of
medical services are under development and probably do
not meet the existing demands. Much effort should be put
into identification, registration and further management of
neurooncology patients in accordance with current western
standards. In this respect, establishing a fully-authorized
brain cancer registry will introduce mandatory standards
for registration processes, which minimize biases and in-
completeness in registration practices. For example, tech-
nical and institutional barriers did not allow us to get
access to the Georgian National Registry Bureau for search-
ing death certificates. Although the missing cases (if any)
most likely would not have affected the incidence rates in
subgroups, establishing a centralized brain tumour registry
will help to overcome any institutional barriers for getting
relevant information.
Conclusion
Despite the above mentioned limitations, our data show
the brain cancer diagnosing procedure quality in a country
with limited economical resources and consequences of
political reorientation. In this respect, regularly reported
data from a brain cancer registry will help to focus on diag-
nostic and missing data issues for improving the validity of
the data. Additionally, population-based epidemiological
data provide important information for the development of
proper national healthcare strategies in relation to neuro-
oncological patients. Regardless of the quality of currently
available data, the current report is the only opportunity to
assess the impact of cancer in the community and cancer
registration should be regarded as a priority in the nation-
wide health policy.
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